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Abstract
Background: ABCC1 and ABCG2 are ubiquitous ATP-binding cassette transmembrane proteins that play an important role
in multidrug resistance (MDR). In this study, we evaluated the possible interaction of vandetanib, an orally administered
drug inhibiting multiple receptor tyrosine kinases, with ABCC1 and ABCG2 in vitro.
Methodology and Principal Findings: MDR cancer cells overexpressing ABCC1 or ABCG2 and their sensitive parental cell
lines were used. MTT assay showed that vandetanib had moderate and almost equal-potent anti-proliferative activity in
both sensitive parental and MDR cancer cells. Concomitant treatment of MDR cells with vandetanib and specific inhibitors of
ABCC1 or ABCG2 did not alter their sensitivity to the former drug. On the other hand, clinically attainable but non-toxic
doses of vandetanib were found to significantly enhance the sensitivity of MDR cancer cells to ABCC1 or ABCG2 substrate
antitumor drugs. Flow cytometric analysis showed that vandetanib treatment significantly increase the intracellular
accumulation of doxorubicin and rhodamine 123, substrates of ABCC1 and ABCG2 respectively, in a dose-dependent
manner (P,0.05). However, no significant effect was shown in sensitive parental cell lines. Reverse transcription-PCR and
Western blot analysis showed that vandetanib did not change the expression of ABCC1 and ABCG2 at both mRNA and
protein levels. Furthermore, total and phosphorylated forms of AKT and ERK1/2 remained unchanged after vandetanib
treatment in both sensitive and MDR cancer cells.
Conclusions: Vandetanib is unlikely to be a substrate of ABCC1 or ABCG2. It overcomes ABCC1- and ABCG2-mediated drug
resistance by inhibiting the transporter activity, independent of the blockade of AKT and ERK1/2 signal transduction
pathways.
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Introduction
Multidrug resistance (MDR), the ability of cancer cells to
acquire resistance to a broad spectrum of structurally and
functionally different anticancer drugs, is thought to be a major
obstacle to the success of cancer chemotherapy. It is often
mediated by overexpression of ATP-binding cassette (ABC)
transporters that remove substrate drugs out of the cells against
a concentration gradient with the use of energy from ATP
hydrolysis [1,2]. 48 different ABC transporters have been
identified in the human genome and are divided into seven
subfamilies (A–G) based on sequence similarities, among which,
ABCB1/P-glycoprotein, ABCC1/MRP1, and ABCG2/BCRP are
the most important members [3].
ABCC1, encoded by the ABCC1 gene on chromosome
16p13.1, was first identified from MDR human NSCLC cell line
H69/ADR. It can transport a broad-spectrum of substrate
anticancer drugs mainly conjugated to glutathione, glucuronate
and sulfate, including vincristine and doxorubicin [4–6]. ABCG2,
also named mitoxantrone resistance-associated protein (MXR),
breast cancer resistance protein (BCRP) or placenta-specific ATP-
binding cassette transporter (ABCP), was first cloned from drug
selected human breast cancer cells MCF-7 and has been reported
to transport chemotherapeutic agents including rhodamine 123,
doxorubicin, mitoxantrone, topotecan and imatinib [2,7–11].
More recently, ABCG2 is considered as a molecular determinant
of the side-population phenotype and ABCG2 expression has been
shown to protect hematopoietic stem cells from cytotoxic agents
PLoS ONE | www.plosone.org 1 April 2009 | Volume 4 | Issue 4 | e5172[12,13]. In fact, high expression of ABCG2 has been found in a
wide variety of cancer stem cells. Enormous effort has been
devoted to the development of inhibitors for ABC transporters in
the hope of circumventing MDR. Three generations of MDR
inhibitors have been exploited, some of which have demonstrated
ability to reverse MDR. Clinical trials evaluating the potential
reversal of anticancer drug resistance by some of these MDR
inhibitors are underway [14].
Tyrosine kinase inhibitors (TKIs) belong to a new class of
anticancer agents, which are believed to work by competing with
the ATP binding site of the catalytic domain of several oncogenic
tyrosine kinases, thereby blocking downstream signal pathways
pivotal for cell replication, survival, metastasis and angiogenesis.
Their usefulness in cancer therapy has been demonstrated in pre-
clinical models and also in the clinics [15,16]. Recently, two
tyrosine kinase inhibitors, STI-571 and AG1393, have been shown
to interact with human ABCB1 and ABCC1, and inhibit their
transport activities [17]. Other TKIs have also been found to
overcome MDR mediated by ABC transporters, including
gefitinib [18,19], erlotinib [20], and lapatinib [21]. These reports
collectively suggest that TKIs may be promising MDR inhibitors.
Vandetanib (Zactima, ZD6474, AstraZeneca Pharmaceuticals,
Macclesfield, UK) is an oral small molecule inhibitor of VEGFR-2
(Flk-1/KDR, vascular endothelial growth factor receptor 2),
EGFR (ErbB1/Her-1, epidermal growth factor receptor), and
RET (rearranged during transfection) tyrosine kinases. It displays
antitumor activity by directly inhibiting tumor cell proliferation
and survival via EGFR and RET inhibition, as well as tumor
angiogenesis via VEGFR inhibition [22]. Recent study reported
that vandetanib may interact with ABCB1 and inhibit its function
[23]. This spurs intensified effort to investigate whether vandeta-
nib can enhance the efficacy of conventional chemotherapeutic
drugs via interaction with ABC transporters in MDR cancer cells.
In this study, we evaluated the efficacy of vandetanib on
ABCC1- and ABCG2- mediated MDR in vitro. Vandetanib
inhibited the transport function of ABCC1 and ABCG2 and
sensitized MDR cancer cells to substrate drugs of the two
transporters. Clinical trial is warranted to study the circumvention
of multidrug anticancer resistance by a combination of vandetanib
with other cytotoxic agents.
Materials and Methods
Chemicals and reagents
3-(4,5-dimethylthiazol-yl)-2,5-diphenyllapatinibrazolium bro-
mide (MTT), vincristine, topotecan, doxorubicin, rhodamine
123, verapamil R-enantiomer (R-VRP) and fumitremorgin C
(FTC) were products of Sigma Chemical Co. Vandetanib was
obtained from AstraZeneca Pharmaceuticals. Dulbecco’s modified
Eagle’s medium (DMEM) and RPMI 1640 were products of
Gibco BRL.. Monoclonal antibodies against ABCB1, ABCC1 and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were prod-
ucts of Santa Cruz Biotechnology, Inc.. Anti-MAP Kinase 1/2
(ERK1/2), p-ERK and p-AKT antibodies were purchased from
Kangchen Co. (Shanghai, China). AKT antibody was a product of
Cell Signaling Technology Inc. (Danvers, MA). ABCG2 antibody
was obtained from Chemicon International, Inc. Other routine
laboratory reagents were obtained from commercial sources of
analytical grade.
Cell culture
The following cell lines were cultured in DMEM or RPMI 1640
containing 10% fetal bovine serum at 37uC in the presence of 5%
CO2: the human oral epidermoid carcinoma MDR cell line
KBV200 which is ABCB1-overexpressing [23], the human
epidermoid carcinoma cell line KB-3-1 and its doxorubicin-
selected derivative ABCC1-overexpressing cell line C-A120 [24];
the human colon carcinoma cell line S1 and its mitoxantrone-
selected derivative ABCG2-overexpressing cell line S1-M1-80
[25].
Cell proliferation assay
MTT assay was used to assess anti-proliferation activity [26].
Briefly, cells were seeded in 96-well plates and allowed to attach
overnight. To determine the cytotoxicity of vandetanib, the drug
at various concentrations was added to the cells and the cells were
incubated at 37uC for 68 h. MTT (5 mg/mL, 20 mL/well) was
then added to the cells for 4 h (37uC). Afterwards, the formazan
product from metabolism of MTT was solubilized in DMSO
(200 mL/well). Optical density was measured at 540 nm, with
background subtraction at 655 nm, using the Model 550
Microplate Reader (BIO-RAD, Hercules, CA, USA). The
concentration required to inhibit cell growth by 50% (IC50) was
calculated from survival curves using the Bliss method [27]. As an
indirect method to assess whether vandetanib is substrate of
ABCC1 and ABCG2, the cytotoxicity assays were repeated by
treating the cells at various concentration of vandetanib with or
without specific inhibitors of the two transporters (ABCC1: R-VRP
5 mmol/L) or (ABCG2: FTC 0.5 mmol/L). To test the effect of
vandetanib on the chemosensitivity of MDR cancer cells,
vincristine (KB-3-1 and its ABCC1-overexpressing derivative) or
topotecan (S1 and its ABCG2-overexpressing derivative) at various
concentrations were added to the cells with or without the addition
of vandetanib. The fold-reversal factor of MDR was calculated by
dividing the IC50 for the cells to vincristine or topotecan in the
absence of vandetanib by that obtained in the presence of
vandetanib.
Doxorubicin and rhodamine 123 accumulation
The effect of vandetanib on the accumulation of doxorubicin
and rhodamine 123 was measured by flow cytometry as previously
described [28]. Briefly, 5610
5 cells were incubated in 6-well plates
and allowed to attach overnight. The cells were treated with
desired concentrations of vandetanib or the vehicle (DMSO) at
37uC for 3 h. Then 10 mmol/L doxorubicin or 5 mmol/L
rhodamine 123 was added and the cells were further incubated
for another 3 h or 0.5 h, respectively. Cells were then collected
and washed twice with ice-cold PBS buffer. Finally, the cells were
resuspended in PBS buffer for flow cytometric analysis (Beckman
Coulter, Cytomics FC500, USA) and 1610
4 cells were counted. R-
VRP was used as a control inhibitor in KB-3-1 and C-A120 cells
whereas FTC was used in S1 and S1-M1-80 cells [23,29].
Preparation of cell lysates and western blot analysis
After vandetanib treatment, cells were harvested and rinsed
twice with ice-cold PBS buffer. Cell extracts were collected in cell
lysis buffer (16PBS, 1% Nonidet P-40, 0.5% sodium deoxycho-
late, 0.1% SDS, 100 mg/mL phenylmethylsulfonyl fluoride,
10 mg/mL aprotinin, 10 mg/ml leupeptin). Equal amounts of cell
lysate from various treatments (100 mg of protein) were resolved by
sodium dodecyl sulfate polycrylamide gel electrophoresis and then
electrophoretically transferred onto polyvinylidene fluoride mem-
branes. After blocked in 5% non-fat milk in TBST buffer
(10mmol/L Tris-HCL, 150mmol/L NaCl, and 0.1% Tween20,
pH 8.0) for 2 h at room temperature, the membranes were
incubated with appropriately diluted primary antibodies overnight
at 4uC. The membranes were then washed thrice with TBST
buffer and incubated with HRP-conjugated secondary antibody at
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with TBST buffer, the protein-antibody complex were visualized
by the enhanced Phototope TM-HRP Detection Kit (Cell
Signaling, USA) and exposed to Kodak medical X-ray processor
(Carestream Health, USA). GAPDH was used as the loading
control.
Reverse transcription-PCR
After vandetanib treatment, total cellular RNA was isolated by
Trizol Reagent RNA extraction kit following manufacturer’s
instruction (Molecular Research Center, USA). The first strand
cDNA was synthesized by Oligo dT primers with reverse
transcriptase (Promega Corp.). PCR primers were 59-cta cct cct
gtg gct gaa tct g-39 (forward) and 59-cat cag ctt gat ccg att gtc t-39
(reverse) for ABCC1; 59-tgg ctg tca tgg ctt cag ta-39 (forward) and
59-gcc acg tga ttc ttc cac aa-39 (reverse) for ABCG2; and 59-ctt tgg
tat cgt gga agg a-39 (forward) and 59-cac cct gtt gct gta gcc-39
(reverse) for GAPDH, respectively. Using the GeneAmp PCR
system 9700 (PE Applied Biosystems, USA), reactions were carried
out at 94uC for 2 min for initial denaturation, and then at 94uC
for 30 s, 58uC for 30 s, and 72uC for 1 min. After 35 cycles of
amplification, additional extensions were carried out at 72uC for
10 min. Products were resolved and examined by 1.5% agarose
gel electrophoresis. Expected PCR products were 151 bp for
ABCC1, 235 bp for ABCG2, and 475 bp for GAPDH,
respectively.
Statistical analysis
All experiments were repeated at least three times. Microsoft
Office Excel 2003 and the statistical software SPSS16.0 were used
in data processing and analyzing the significance using the
student’s t-test. All P-values were two-sided, and the statistical
significance was determined at P,0.05.
Results
ABCC1 and ABCG2 do not confer resistance to
vandetanib
C-A120 and S1-M1-80 are drug resistance models with
overexpression of ABCC1 and ABCG2, respectively
(Figure. 1A). The basal expressions of ABCC1 and ABCG2 in
the parental cell lines were nearly undetectable. MTT assay was
performed to examine the cytotoxic effect of vandetanib on these
MDR cells. Vandetanib showed moderate cytotoxic effect on both
of the two pairs of parental and resistant cell lines (Figure. 2 and
Table 1). No significant difference in the cytotoxicity of
vandetanib was observed between the parental and resistant cells.
The IC50 values of vandetanib alone for KB-3-1, C-A120, S1 and
S1-M1-80 cells were 4.198, 4.235, 1.291, and 1.398 mmol/L,
respectively. Cytotoxicity assays were repeated with a combination
of vandetanib with inhibitors of ABCC1 (R-VRP; 5 mmol/L) or
ABCG2 (FTC; 0.5 mmol/L) in the parental and resistant cells of
KB-3-1 and S1, respectively. The drug combination did not
change the cytotoxic effect of vandetanib (Figure. 2 and
Table 1). Thus, overexpression of ABCC1 and ABCG2 do not
confer resistance to vandetanib. Moreover, vandetanib is unlikely
to be a substrate for ABCC1 and ABCG2.
Vandetanib sensitizes ABCC1- and ABCG2-
overexpressing cells to chemotherapeutic drugs
As shown in Figure. 2, more than 90% of cells survived when
treated with vandetanib alone up to 1 mmol/L in KB-3-1 and C-
A120 cells, and up to 0.2 mmol/L in S1 and S1-M1-80 cells.
Therefore, vandetanib at a concentration of up to 1 mmol/L (in
KB-3-1 and C-A120) or 0.2 mmol/L (in S1 and S1-M1-80) was
chosen for combination treatment with known ABCC1 (vincris-
tine) or ABCG2 (topotecan) substrate anticancer drugs. The IC50
values of vincristine or topotecan in the two pairs of parental and
MDR cell lines when treated alone or in combination with
different concentrations of vandetanib are shown in Table 1. R-
VRP and FTC (inhibitor for ABCC1 and ABCG2, respectively)
were used in place of vandetanib as positive control to confirm the
mechanism of drug resistance in the MDR cell line models. In
ABCC1-overexpressing C-A120 and ABCG2-overexpressing S1-
M1-80 cells, vandetanib produced a significant dose-dependent
enhancement in the cytotoxicity of vincristine and topotecan,
respectively (P,0.05). The fold-reversal of MDR by 1 mmol/L
vandetanib in C-A120 cells was about 7.5, while that by
0.2 mmol/L vandetanib in S1-M1-80 cells was about 9.5,
suggesting that vandetanib is more potent in reversing ABCG2-
mediated MDR. As a control, vandetanib did not increase
chemosensitivity in the sensitive parental cells.
Figure 1. Effect of vandetanib on the expression of ABCC1 and
ABCG2 in MDR cells. The protein expression of ABCB1, ABCC1 and
ABCG2 in KBV200 (lane 1), S1 (lane 2), S1-M1-80 (lane 3), KB-3-1 (lane 4)
and C-A120 (lane 5) cell lines without treatment was measured by
Western blot analysis (A). C-A120 (B) and S1-M1-80 cells (C) were treated
with vandetanib at indicated concentrations for 24, 48, or 72 h. The
expression of ABCC1 and ABCG2 at both protein and mRNA level were
detected as described in ‘‘Materials and Methods’’. A representative
result is shown from at least thee independent experiments.
doi:10.1371/journal.pone.0005172.g001
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The results above indicated that vandetanib could enhance the
sensitivity of MDR cancer cells to certain ABCC1 and ABCG2
substrate anticancer drugs. To understand the underlying
mechanisms, the intracellular accumulation of doxorubicin and
rhodamine 123 in the presence or absence of vandetanib was
examined by flow cytometric analysis. Upon treatment with the
fluorescent substrates alone, intracellular fluorescence intensity of
doxorubicin was significantly higher in the KB-3-1 (3.1-fold) and
S1 cells (4.9-fold) than that in the MDR C-A120 and S1-M1-80
cells whereas that of rhodamine 123 was 11.4-fold in KB-3-1 and
10.6-fold in S1 cells compared with C-A120 and S1-M1-80 cells,
respectively (Figure. 3). When the cells were treated in the
presence of vandetanib, the intracellular accumulation of doxoru-
bicin was 1.3-, 1.5- and 1.9-fold higher in C-A120 cells in the
presence of 0.5, 1 and 2 mmol/L vandetanib, and 1.6-, 2.1- and
2.6-fold higher in S1-M1-80 cells in the presence of 0.05, 0.1 and
0.2 mmol/L vandetanib, respectively (Figure. 3 A and B). As
shown in Figure. 3 C and D, vandetanib at 0. 5, 1 and 2 mmol/
L increased the intracellular accumulation of rhodamine 123 by
2.2-, 3.1- and 4.6-fold in C-A120 cells, and increased the
intracellular accumulation of rhodamine 123 by 3.0-, 4.3- and
5.3-fold in S1-M1-80 cells at the concentration of 0.05, 0.1 and
0.2 mmol/L, respectively. However, no significant change in the
intracellular accumulation of doxorubicin and rhodamine 123 was
observed in the parental KB-3-1 and S1 cells upon combination
treatment with vandetanib. Taken together, these results suggest
that vandetanib is able to modulate ABCC1- and ABCG2-
mediated transport in MDR cells.
Table 1. Effect of vandetanib on reversing ABCC1- and
ABCG2-mediated drug resistance
Compounds IC506SD mmol/L (fold-reversal)
KB-3-1 C-A120
Vandetanib 4.19860.175 (1.00) 4.23560.419 (1.00)
+5 mmol/L R-VRP 4.55360.152 (0.92) 4.52260.776 (0.94)
Vincristine 0.00340960.000169 (1.00) 0.65460.040 (1.00)
+0.25 mmol/L vandetanib 0.00347660.000336 (0.98) 0.35260.025 (1.86)*
+0.5 mmol/L vandetanib 0.00339460.000250 (1.00) 0.20960.023 (3.13)**
+1 mmol/L vandetanib 0.00338260.000394 (1.01) 0.08760.013 (7.52)**
+5 mmol/L R-VRP 0.00314760.000104 (1.08) 0.06960.010 (9.49)**
S1 S1-M1-80
Vandetanib 1.29160.041 (1.00) 1.39860.088 (1.00)
+0.5 mmol/L FTC 1.22960.118 (1.05) 1.41060.251 (0.99)
Topotecan 0.28260.020 (1.00) 11.11660.635 (1.00)
+0.05 mmol/L vandetanib 0.25960.023 (1.09) 5.34460.310 (2.08)*
+0.1 mmol/L vandetanib 0.26960.044 (1.05) 2.20560.098 (5.04)**
+0.2 mmol/L vandetanib 0.27260.025 (1.04) 1.24060.097 (8.96)**
+0.5 mmol/L FTC 0.27760.029 (1.02) 0.90560.066 (12.3)**
Cell survival was determined by MTT assays as described in ‘‘Materials and
Methods’’. Data are the means6standard deviation (SD) of at least three
independent experiments performed in triplicate. The fold-reversal of MDR was
calculated by dividing the IC50 for cells with the anticancer drugs in the
absence of vandetanib by that obtained in the presence of vandetanib.
*and ** represent P,0.05 and P,0.01, respectively, for values versus that
obtained in the absence of vandetanib.
doi:10.1371/journal.pone.0005172.t001
Figure 2. Cytotoxicity of vandetanib in the sensitive parental
and drug-resistant cancer cell lines. MTT cytotoxicity assay was
used to measure cell survival in KB-3-1 (A), C-A120 (B), S1 (C) and S1-M1-
80 cells treated with vandetanib alone or in combination with ABCC1
inhibitor R-VRP or ABCG2 inhibitor FTC, as described in ‘‘Materials and
Methods’’. Data points represent the means6SD of at least three
independent experiments performed in triplicate.
doi:10.1371/journal.pone.0005172.g002
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PLoS ONE | www.plosone.org 4 April 2009 | Volume 4 | Issue 4 | e5172Figure 3. Effect of vandetanib on the accumulation of doxorubicin and rhodamine 123. The accumulation of doxorubicin (A and B) and
rhodamine 123 (C and D) was measured by flow cytometric analysis as described in ‘‘Materials and Methods’’. The results are presented as fold
change in fluorescence intensity relative to control MDR cells. They are calculated by dividing the fluorescence intensity of each sample with that of
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The reversal of ABCC1- and ABCG2-mediated MDR can be
achieved either by inhibiting their function or decreasing their
expression. The effect of vandetanib on the expression of ABCC1
and ABCG2 were measured by western blot analysis and reverse
transcription-PCR. ABCC1 and ABCG2 expressions were not
significantly altered at the protein or mRNA level (Figure. 1 B
and C) after treatment with vandetanib at up to 1 mmol/L and
0.2 mmol/L in C-A120 and S1-M1-80 cells, respectively. The
result suggests that the reversal of MDR was not obtained through
inhibition of expressions of the two transporters.
Vandetanib dose not block the phosphorylation of AKT
and ERK1/2
As common downstream markers of most cytokine-receptor
signal transduction pathways, the phosphorylation of AKT and/or
ERK1/2 is usually used to indicate the involvement of these
pathways in the activity of the tested compounds. To determine
whether the MDR reversal activity of vandetanib was related to
the change of AKT and ERK1/2, total and phosphorylated forms
of AKT and ERK1/2 were measured after treatment with
vandetanib at concentrations used in the MTT assays. As shown in
Figure. 4 and S1, after vandetanib treatment, total and
phosphorylated AKT and ERK1/2 were not significantly changed
in all the cell lines tested. The results suggest that the MDR
reversal effect by vandetanib in MDR C-A120 and S1-M1-80 cells
is independent of the inhibition of AKT and ERK1/2 phosphor-
ylation.
Discussion
Since Gleevec (imatinib mesylate, STI571) was approved by the
FDA as first-line treatment for chronic myeloid leukemia with the
oncoprotein BCR-ABL expression in 2001, molecular targeted
therapy for various cancers has become an area of intense basic
science and clinical research. Cytokine receptor signal transduc-
tion pathways are important mediators of cancer cell oncogenesis,
proliferation, maintenance and survival. Among them, EGFR and
VEGFR-2 pathways, important in cancer cells and cancer-
associated endothelial cells, respectively, are the most extensively
studied [30–32]. Different approaches have been exploited to
inhibit these two pathways including monoclonal antibodies
targeting EGFR and VEGFR, VEGF Trap, and TKIs [16,33].
Currently, the potential anticancer activity of a number of TKIs,
including gefitinib, erlotinib, EKB-569, EKB-569, HKI-272, CI-
1033, and vandetanib, are studied in different stages of clinical
trials [15].
Vandetanib (Zactima, ZD6474) is an oral small molecule
inhibitor of VEGFR-2, EGFR, and RET tyrosine kinases. In vitro
studies demonstrated its selective inhibition on VEGFR-2, EGFR,
VEGFR-3 and RET tyrosine kinase activities, with IC50 of 40,
110, 500 and 100 nmol/L, respectively [34,35]. Vandetanib has
been shown to inhibit the proliferation of vascular endothelial
growth factor-A -stimulated human umbilical vein endothelial cell
in vitro (IC50 60 nmol/L). Further studies demonstrated that it
inhibits proliferation and induce apoptosis of cancer cells in vitro
and that it also inhibits angiogenesis and progression of many
xenograft and orthotropic nude mice models, including non-small
cell lung cancer [36], small-cell lung cancer [37], gastric cancer
[38], nervous system tumors [39], pancreatic cancer [40], colon
cancer [41], hepatocellular carcinoma [42], and prostate cancer
[43], via inhibiting phosphorylation of AKT and/or ERK1/2.
Unlike other chemotherapeutic agents that readily develop cross-
resistance towards other structurally related or unrelated com-
pounds, vandetanib has not been reported to develop cross-
resistance to prior chemotherapeutic agents, either in vivo or in vitro
[44]. Phase I studies showed that vandetanib is generally well
tolerated at dose up to 300 mg/day, with a once-daily oral
MDR cells treated with doxorubicin or rhodamine 123 alone. Columns, means of triplicate determinations; bars, SD. * , P,0.05; **, P,0.01, versus the
MDR control group, respectively.
doi:10.1371/journal.pone.0005172.g003
Figure 4. Effect of vandetanib on the blockade of AKT and
ERK1/2 phosphorylation. KB-3-1 (A), C-A120 (B), S1 (C) and S1-M1-80
cells (D) were treated with vandetanib at indicated concentrations for
24, 48, or 72 h. The expressions of AKT, pAKT, ERK1/2 and pERK1/2 were
examined by Western blot analysis, with GAPDH as the loading control
as described in ‘‘Materials and Methods’’. Independent experiments
were performed at least three times and result from a representative
experiment is shown.
doi:10.1371/journal.pone.0005172.g004
Reversal of MDR by Vandetanib
PLoS ONE | www.plosone.org 6 April 2009 | Volume 4 | Issue 4 | e5172administration schedule [45,46]. Phase II evaluation in patients
with advanced refractory NSCLC demonstrated improvements in
progression-free survival both as monotherapy (versus gefitinib)
and in combination with docetaxel (versus docetaxel alone) [47].
These positive outcomes have led to the initiation of Phase III
trials of vandetanib in advanced NSCLC. Clinical development is
also ongoing in other tumor types and encouraging evidence of
antitumor activity has been reported [47].
ABC transporters-mediated MDR is a major obstacle to cancer
chemotherapy. Quinazolines are some of the most promising
inhibitors of receptor tyrosine kinases by competition with ATP for
ATP-binding site [48]. Many TKIs with core structure of
quinazolines have been demonstrated to inhibit the function of
ABC transporters and reverse MDR, including gefitinib and
erlotinib [19,20]. Vandetanib shares the same quinazoline moiety
with other TKIs, evoking the possibility that it can also interact
with ABC transporters. A recent report has demonstrated the
interaction between vandetanib and ABCB1 [23].
In the present study, our data showed that overexpression of
ABCC1 and ABCG2 confer drug resistance to the drug-selected
resistant sublines C-A120 and S1-M1-80, respectively. C-A120
cells were about 190-fold resistant to vincristine compared with its
parental KB-3-1 cell line whereas S1-M1-80 was about 40-fold
resistant to topotecan compared with its parental S1 cell line
(Table 1). Both of the two resistant cell lines had similar sensitivity
to vandetanib compared with sensitive parental cells. More
importantly, co-incubation with ABCC1 inhibitor R-verapamil
or ABCG2 inhibitor fumitremorgin C did not change the
sensitivity of the tested cells to vandetanib, strongly implying that
overexpression of functional ABCC1 and ABCG2 dose not confer
resistance to vandetanib, and that vandetanib is not a substrate of
ABCC1 and ABCG2. The latter property probably explains why
vandetanib is devoid of cross-resistance to prior chemotherapeutic
agents in clinical trials [44]. Our data also demonstrated the ability
of vandetanib to enhance cytotoxicity of known ABCC1 substrate
vincristine and ABCG2 substrate topotecan in MDR cells
(Table 1, P,0.05). Vandetanib at 1 mmol/L significantly
increased the sensitivity of C-A120 cells to vincristine by 7.5-fold
and 0.2 mmol/L of vandetanib enhanced the sensitivity of S1-M1-
80 cells to topotecan by 9-fold. While vandetanib at 0.2 to
1 mmol/L only affect cell proliferation very minimally, the two
concentrations are readily attainable clinically [46] (Figure. 2). As
a control, vandetanib at the same concentrations did not have any
significant effect on the sensitive parental cells, suggesting that the
sensitization of the resistant cells by vandetanib is due to its specific
effect on ABCC1 and ABCG2.
To investigate the mechanism of ABCC1- and ABCG2-
mediated MDR reversal by vandetanib, ABCC1 and ABCG2
expression and transport activity were examined. Consistent with
the overexpression and therefore higher transport function of
ABCC1 and ABCG2, C-A120 and S1-M1-80 cells had lower
intracellular accumulation of doxorubicin and rhodamine 123,
respectively (Figure. 3). Vandetanib treatment significantly
increased the accumulation of doxorubicin and rhodamine 123
in a dose-dependent manner (P,0.05). However, no significant
change was found in the parental KB-3-1 and S1 cells. Taken
together, these data strongly advocate that vandetanib can inhibit
the transport function of ABCC1 and ABCG2, thereby increasing
the intracellular concentration of their substrate chemotherapeutic
drugs. However, vandetanib treatment did not change the
expression of ABCC1 and ABCG2 at both protein and mRNA
level in the cells (Figure. 1 B and C). It has been reported that
activation of PI3K/AKT and/or ERK pathways is related to
resistance to conventional chemotherapeutic agents [49–51]. On
the other hand, vandetanib treatment is associated with AKT
and/or ERK1/2 inhibition in vitro or in vivo. However, our data
revealed no significant alteration of the phosphorylation of AKT
and ERK1/2 in the tested cell lines (Figure. 4 and S1),
suggesting that inhibition of AKT and ERK1/2 is not involved in
the reversal of ABCC1 or ABCG2-mediated MDR by vandetanib.
The binding of ATP to the nucleotide-binding site of ABC
transporter is essential for substrate transport, and the hydrolysis of
ATP by ATPase activity of the transporter is critical for restoring
the transporter to its active conformational state [52]. Inhibition of
ABC transporter activity by modulators can be achieved by
blockage of (1) specific recognition of the substrate, (2) binding of
ATP, (3) ATP hydrolysis, or (4) coupling of ATP hydrolysis to
translocation of the substrate [14]. The drug efflux function of
ABCB1 and ABCG2 is coupled to ATP hydrolysis which is
stimulated in the presence of ABCB1 and ABCG2 substrates.
Based on their effect on ATPase activity of ABC transporters,
compounds (anticancer drugs and MDR reversing agents) can be
categorized into three distinct classes. The first class of compounds
stimulates ATPase activity at low concentrations but inhibits the
activity at high concentrations, the second class of compounds
enhances ATPase activity in a dose-dependent manner without
any inhibition, whereas the third class of compounds inhibits both
basal and stimulated ATPase activity [53]. Erlotinib and lapatinib,
two other tyrosine kinase inhibitors, have been demonstrated to
reverse ABCB1- and ABCG2-mediated MDR and can stimulate
the ATPase activities of the transporters at low concentrations
[20,21]. It has been reported that vandetanib can directly interact
with ABCB1 and increase the ATPase activity of ABCB1 in a
dose-dependent manner [23]. This suggests that vandetanib
belongs to the second class of compounds to interact with ABC
transporters.
The concept of cancer stem cells, suggesting that cancers
originate and are maintained by a rare fraction of cells with stem
cell properties, has played a pivotal role in changing our view of
carcinogenesis and chemotherapy [14]. Recent studies suggested
that cancer stem cells may be responsible for tumorigenesis and
contribute to resistance to cancer chemotherapy [14,54]. ABCG2
is found to be expressed in a wide variety of cancer stem cells and
may be responsible for their drug resistance phenotype [55]. Our
data showed that vandetanib was able to inhibit ABCG2 transport
activity and to reverse MDR even at low concentration. It could
be used in conjunction with other conventional anticancer drugs to
eradicate the cancer stem cells.
In conclusion, vandetanib reverses ABCC1- and ABCG2-
mediated MDR by directly inhibiting ABCC1 and ABCG2
function at clinically relevant concentrations, resulting in an
increase of intracellular concentrations of substrate chemothera-
peutic drugs to the two transporters. The MDR reversal seems to
be independent of the blockade of tyrosine kinases. Our results
suggest that vandetanib can be used in conjunction with
conventional ABCC1 and ABCG2 substrate anticancer drugs to
combat the problem of multidrug resistance in the clinic.
Supporting Information
Figure S1
Found at: doi:10.1371/journal.pone.0005172.s001 (0.16 MB
PDF)
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